title: Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?
authors.forename: Mar
authors.initials: M
authors.lastname: Mallo
authors.forename: Marta
authors.initials: M
authors.lastname: Salido
authors.forename: Blanca
authors.initials: B
authors.lastname: Espinet
authors.forename: José
authors.initials: J
authors.lastname: Cervera
authors.forename: Anna
authors.initials: A
authors.lastname: Canellas
authors.forename: Juan Carlos
authors.initials: JC
authors.lastname: Pajuelo
authors.forename: Carmen
authors.initials: C
authors.lastname: Pedro
authors.forename: Lourdes
authors.initials: L
authors.lastname: Florensa
authors.forename: Miguel Angel
authors.initials: MA
authors.lastname: Sanz
authors.forename: Francesc
authors.initials: F
authors.lastname: Solé
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002869:Chromosome Aberrations / Q000187:drug effects*; D002890:Chromosomes, Human, Pair 20 / Q000235:genetics*; D004273:DNA, Neoplasm / Q000235:genetics; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D015996:Survival Rate; D014178:Translocation, Genetic; D014212:Tretinoin / Q000008:administration & dosage
chemical_list: D004273:DNA, Neoplasm; D014212:Tretinoin; D015255:Idarubicin